Assessment of Olfactory Dysfunction in SARS CoV-2 (COVID-19) Infection

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

81 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-07-02

Study Completion Date

2023-03-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is designed to investigate the acuity of olfactory dysfunction in COVID-19 positive patients in the United Kingdom. In particular defining severity with objective testing and determining if this has any predictive value on the outcome of the SARS CoV-2 infection. In addition, this study will strive to determine duration / natural history of olfactory dysfunction in these patients in respect to a positive SARS CoV-2 diagnosis. It should also demonstrate the impact of olfactory dysfunction on patient Quality of Life (QOL).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

COVID-19: Post-covid Olfactory Disorders Assessment

NCT04799977

Olfaction Disorders

COMPLETED

Evaluation of Two Methods of Olfactory Rehabilitation in Post-viral Loss of Smell: Classic and Intensive

NCT04598763

Olfaction Disorders

UNKNOWN NA

Longitudinal At Home Smell Testing to Detect Infection by SARS-CoV-2

NCT05040659

Anosmia Asymptomatic COVID-19 COVID-19 Respiratory Infection +3 more

ACTIVE_NOT_RECRUITING

Mindfulness-Based Stress Reduction Versus Lifestyle Intervention for Long-Haul Covid-19 Parosmia

NCT06789952

COVID-19

TERMINATED NA

Olfactory Training for Olfactory Dysfunction After Coronavirus Disease - 19 (COVID-19)

NCT04764981

Covid19 SARS-CoV Infection Olfactory Disorder +1 more

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The main objective of this study is to evaluate olfactory acuity by means of a multidimensional assessment protocol to objectively demonstrate the severity of olfactory dysfunction in patients diagnosed with SARS CoV-2. The University of Pennsylvania Smell Identification Test (UPSIT) will be used to assess olfactory function in newly diagnosed patients and also existing patients longitudinally over a 12-month period. This is to document onset (where possible) and rate of progress of olfactory dysfunction.

In relevant cases, the investigators will correlate their findings with severity of the Acute Respiratory Distress Syndrome (ARDS) arising as a result of the infection - characterised as mild, moderate and severe according to the Berlin classification. The investigators will therefore determine if the degree of olfactory dysfunction correlates in any manner to the severity of ARDS developed in a positive SARS CoV-2 patient and if it offers any prognosticative applications.

The investigators will also examine the impact of the symptom of olfactory dysfunction on patient Quality of Life using two validated tools known as the Questionnaire of Olfactory Disorders for English speakers (eQOD) and the SNOT-22 questionnaire.

Furthermore, outcomes will be explored and stratified in terms of age, gender and ethnicity

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Olfactory Disorder COVID19 SARS-CoV-2 Anosmia Microsomia Smell Disorder Quality of Life

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients who are presenting to hospital with symptoms of SARS CoV-2 infection.
* Patients who go on to develop a positive SARS CoV-2 test.
* Patients who can give a valid written informed consent.
* Patients who are motivated to participate in the study.
* Adult patients aged 18 years - 85 years.

Exclusion Criteria

* Patients who cannot give a valid written informed consent.
* Patients who are not willing or not motivated to participate in the study.
* Patients with negative SARS CoV-2 tests.
* Patients with nasal pathologies like severe deviated nasal septum, nasal masses, head trauma or previously known chronic rhinosinusitis with polyps or on medication for more than 6 months/year for at least one year for chronic rhinosinusitis.
* Patients with any diagnosed neurological disease known to affect olfactory function will be excluded from the study.
* Patients unable to read in the English language.

Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No